Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Epithelial membrane protein 3 (EMP3)
- Target
- EMP3
- Molecular classification
- Tetraspan membrane protein, Peripheral myelin protein 22 kDa (PMP22) family member, Integral membrane protein
01
Overview
EMP3 is a 163-amino acid integral membrane protein (~18 kDa) encoded on chromosome 19q13.3. It structurally comprises four transmembrane domains, two extracellular loops (18 and 41 amino acids, respectively), and a short intracellular loop. EMP3 is classified as a tetraspanin membrane protein and shares homology with the PMP22 family, associated with myelin and membrane organization. Functionally, EMP3 regulates cell–cell interactions, signal transduction, and membrane organization, thereby influencing processes such as cell survival, migration, and tumor progression. It interacts with critical oncogenic membrane proteins (receptor tyrosine kinases, integrins, transforming growth factor beta receptor 2) to modulate cancer-relevant pathways (e.g., HER2/PI3K/Akt, TGF-beta/Smad, FAK/SRC, MAPK/ERK). EMP3's overexpression in tumors, particularly glioblastoma, is linked to poor prognosis and aggressive tumor phenotypes. It is also implicated as a regulator in immune cell biology
- Other names
- EMP3YMPHNMP-1EMP-3Hematopoietic neural membrane protein 1Protein YMP
02
Mechanism of action
EMP3 stabilizes and regulates receptor tyrosine kinases (RTKs) such as EGFR and HER2, modulates integrin signaling, and influences the TGF-beta/Smad and PI3K/Akt signaling pathways, thereby impacting cancer cell proliferation and migration
03
Biological functions
Regulation of cell proliferationCell survivalCell migrationCell adhesionSignal transductionApoptosisImmune regulation (T cell, macrophage interaction modulation)
04
Disease associations
Cancer (glioblastoma, breast, nasopharyngeal, gastric, bladder, laryngeal, and endometrial cancers)Tumor prognosisRegulation of oncogenic signaling
05
Safety considerations
Therapeutic targeting may encounter specificity challenges due to EMP3's widespread tissue expressionpossible effects on normal epithelial and hematopoietic cellslack of direct catalytic domains, which may complicate drug design
06
Interacting drugs
No direct FDA-approved drugs specifically targeting EMP3 are currently listed; however, EMP3 modulates pathways influenced by targeted drugs in oncogenic signaling (e.g., EGFR, HER2 inhibitors)
07
Biomarkers
EMP3 expression levels serve as potential biomarkers for tumor prognosis and patient stratification, particularly in glioblastoma and other cancers
Beyond the preview
Go deeper on Epithelial membrane protein 3 (EMP3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Epithelial membrane protein 3 (EMP3).